WuXi Biologics: Upgraded Growth Outlook and Higher DCF-Based Target Price Support Buy Rating
Tip Ranks·- Wu Jing from China Securities has maintained a buy rating on WuXi Biologics while setting a target price of 60.00 HKD. - The rating is supported by strong 2026 first-half financial results, growing order backlogs, and upgraded multi-year revenue guidance from management. - Additional growth drivers include global capacity expansion, accelerated hiring, and the emerging biosimilar manufacturing business acting as a new profit pillar.